


Details:
The funding aims to develop a novel mRNA-based malaria transmission-blocking vaccine. It targets Pvs230, a sexual stage protein of the parasite, that induces potent and long-lasting transmission blocking immunity and interrupt transmission of P. vivax from human to mosquito.
Lead Product(s): mRNA Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Product Type: Vaccine
Partner/Sponsor/Collaborator: GHIT
Deal Size: $0.5 million Upfront Cash: Undisclosed
Deal Type: Funding March 30, 2023